Journal article : Review
Artificial intelligence applications in inherited retinal dystrophies
- Abstract:
- Purpose: Inherited retinal dystrophies (IRDs) are a heterogeneous group of diseases characterized by genotypic and phenotypic variability and are among the leading causes of blindness in the working-age population in developed countries. Despite advancements in genetic testing, obtaining a molecular diagnosis remains a lengthy and challenging process due to limited resources and high costs. Artificial intelligence (AI) offers promising solutions to streamline diagnostic pathways and improve clinical outcomes. Methods: We reviewed current literature on AI-driven approaches in IRDs. Results: AI models have demonstrated potential in predicting disease-causing variants, distinguishing phenotypically similar IRDs, and segmenting retinal layers. However, their routine clinical adoption remains limited. Efforts are ongoing to lower genetic testing costs, reduce diagnostic delays, and enhance molecular diagnostic yield. Future applications may include genetic counselling, prediction of IRD progression, evaluation of novel mutation pathogenicity, identification of gene therapy candidates, and prediction of personalized outcomes post-treatment. Barriers to widespread AI adoption include a lack of standardized nomenclature, ethnic and regional variations, inconsistent multimodal imaging quality, data ownership concerns, clinical safety, cybersecurity, and the opaque nature of AI decision-making, known as the “black-box” problem. Conclusions: AI models have shown promise in diagnosing IRDs, predicting causative genes, and segmenting retinal layers. While AI has the potential to revolutionize IRD diagnosis and management, significant challenges must be addressed. Continued research and collaboration are crucial to overcoming these barriers and unlocking AI’s full potential in IRDs.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.4MB, Terms of use)
-
- Publisher copy:
- 10.1007/s00417-025-06956-w
Authors
+ National Institute for Health and Care Research Applied Research Collaboration Oxford and Thames Valley
More from this funder
- Funder identifier:
- 10.13039/501100023233
- Grant:
- BRC4 Gene and Cell Therapy, NIHR203311.
- Publisher:
- Springer
- Journal:
- Graefe's Archive for Clinical and Experimental Ophthalmology More from this journal
- Volume:
- 264
- Issue:
- 2
- Pages:
- 299-307
- Publication date:
- 2025-11-05
- Acceptance date:
- 2025-08-18
- DOI:
- EISSN:
-
1435702X
- ISSN:
-
0721832X
- Language:
-
English
- Keywords:
- Subtype:
-
Review
- Pubs id:
-
2325380
- Local pid:
-
pubs:2325380
- Source identifiers:
-
3781891
- Deposit date:
-
2026-02-20
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2025
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record